LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sensitive Analyzer Detects Blood Biomarker for Traumatic Brain Injury

By LabMedica International staff writers
Posted on 18 Aug 2015
Print article
Image: The Single Molecule Array (Simoa) HD-1 Analyzer (Photo courtesy of Quanterix Corporation).
Image: The Single Molecule Array (Simoa) HD-1 Analyzer (Photo courtesy of Quanterix Corporation).
Traumatic brain injury (TBI) is recognized as the signature injury in military personnel deployed for combat operations, and combat injuries and injuries in non-deployed settings have resulted in more than 300,000 TBI cases, with many experiencing multiple TBIs.

Tau is a microtubule-associated protein that functions as a structural element in the axonal cytoskeleton and elevations of tau concentration are an indication of axonal injury and are observed in the cerebral spinal fluid and peripheral blood of patients with severe TBI, professional boxers, and concussed athletes.

Scientists at the National Institute of Nursing Research, (NINR; Bethesda, MD, USA) and their colleagues carried out an observational assessment from September 2012 to August 2014 on 70 military patients with self-reported TBI and compared their tau concentrations in blood plasma to a control group consisting of 28 subjects. Non-fasting blood samples were collected into plastic dipotassium EDTA tubes, placed on ice, and centrifuged at 2,000 × g for 15 minutes at 4 °C, and plasma was aliquoted.

Tau concentrations in plasma samples were measured with a digital array technology (Quanterix Corporation; Lexington, MA, USA), which uses a single-molecule enzyme-linked immunoarray (Simoa) method. The Simoa Human Total Tau assay uses a combination of a monoclonal capture antibody that reacts with a linear epitope in the mid-region of all tau isoforms, and a detection antibody that reacts with a linear epitope in the N-terminus of total tau. The limit of detection for this assay is 0.012 pg/mL.

A significantly elevated concentration of total tau with a mean of 1.13 ± 0.78 pg/mL was found in the self-reported TBI group compared with the control group whose mean was 0.63 ± 0.48 pg/mL. Within the self-reported TBI cases, plasma total tau concentrations were significantly associated with having a medical record of TBI compared with self-reported TBI only. The severity of total post concussive symptoms correlated with total tau concentrations in the self-reported TBI group. They also found that participants with three or more deployment-related TBIs had significantly higher levels of tau compared with participants who had fewer TBIs.

The authors concluded that increases in total tau concentration in the peripheral blood in military personnel with multiple TBIs and chronic post concussive disorder (PCD) symptoms suggest that tau accumulations may contribute to chronic neurological symptoms following TBI. E. Kevin Hrusovsky, PhD, CEO of Quanterix Corporation, said, “This is one of the many studies in which Simoa is being used to further understand and quantify the long term effects of TBI and we are pleased to be working with NINR to continue our mission to understand what is going on in the human body and, in turn, improve the quality of care.” The study was published on August 3, 2015, in the journal JAMA Neurology.

Related Links:

National Institute of Nursing Research  
Quanterix Corporation 


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.